Shire posts strong Q1 results
This article was originally published in Scrip
Shire has beaten analyst expectations for the first quarter, with product sales increasing by 9% (13% in constant currencies) and total revenues up by 11% (15% in constant currencies), driven by strong sales of ADHD drug Vyvanse and orphan drug Cinryze
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.